Premium
Effect of halofenate on serum lipids
Author(s) -
Aronow Wilbert S.,
Harding Phillip R.,
Khursheed Mohammed,
Vangrow Jack S.,
Papageorge's Nicholas P.,
Mays James
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973143358
Subject(s) - hypertriglyceridemia , myocardial infarction , placebo , triglyceride , medicine , blood lipids , coronary heart disease , serum concentration , cardiology , gastroenterology , cholesterol , alternative medicine , pathology
Forty‐eight people with hypertriglyceridemia associated with types III, IV, V, and nondefinitive lipoprotein patterns participated in a double‐blind 14 month study to determine the effects of halofenate on serum lipids. One month after starting dietary control, a 2 month control period began. After this, 25 patients were given placebo and 23 patients were given halofenate for 48 weeks. Five of the 35 patients with coronary heart disease developed a myocardial infarction and died within 14 months. Halofenate lowered mean serum triglyceride levels 49%j from the control period in comparison with placebo but did not significantly tower mean serum cholesterollevels. Halofenate also did not significantly affect myocardial infarction or mortality rate.